Short Interest in Integra LifeSciences Holdings Co. (NASDAQ:IART) Decreases By 16.8%

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) was the target of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 3,310,000 shares, a drop of 16.8% from the March 15th total of 3,980,000 shares. Approximately 5.0% of the company's stock are short sold. Based on an average daily trading volume, of 678,100 shares, the short-interest ratio is presently 4.9 days.

Wall Street Analyst Weigh In

IART has been the subject of several research analyst reports. Truist Financial lowered their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a report on Friday, April 11th. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Integra LifeSciences presently has an average rating of "Hold" and a consensus target price of $22.71.

Integra LifeSciences Stock Up 1.7 %

Shares of IART traded up $0.28 on Thursday, hitting $16.54. 48,213 shares of the stock traded hands, compared to its average volume of 1,037,075. The company has a market capitalization of $1.28 billion, a PE ratio of -183.59, a P/E/G ratio of 0.73 and a beta of 1.24. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The business has a 50 day simple moving average of $20.79 and a 200 day simple moving average of $22.19. Integra LifeSciences has a one year low of $14.45 and a one year high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. During the same quarter last year, the firm earned $0.89 earnings per share. The firm's quarterly revenue was up 11.5% compared to the same quarter last year. As a group, equities analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently added to or reduced their stakes in the stock. Quadrant Capital Group LLC grew its position in Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after purchasing an additional 1,371 shares during the period. Sterling Capital Management LLC grew its position in shares of Integra LifeSciences by 821.7% during the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after acquiring an additional 1,931 shares during the period. Nisa Investment Advisors LLC grew its position in shares of Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after acquiring an additional 2,800 shares during the period. Covestor Ltd grew its position in shares of Integra LifeSciences by 61.8% during the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after acquiring an additional 2,071 shares during the period. Finally, Empowered Funds LLC bought a new stake in shares of Integra LifeSciences during the 4th quarter valued at $180,000. Institutional investors own 84.78% of the company's stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.